Table 2.
Main Characteristics of Included Studies in Meta-Analysis for COVID-19 Mortality.
| Author, year | Country | Study design | Sample | Gender (M/F) |
Median age (years) |
Type of CCVD |
With CCVD | Without CCVD | Incidence of CCVD |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Survivor | Death | Survivor | Death | ||||||||
| Mehra, M. R., 2020 | USA | Retrospective | 8,910 | 5,518/3,392 | NR | CaVD | 907(90%) | 103(10%) | 7,488(95%) | 412(5%) | 11.34% |
| Inciardi, R. M., 2020 | Italy | Retrospective | 99 | 88/11 | 67.0 (48.0–86.0) | CaVD | 34(64%) | 19(36%) | 39(85%) | 7(15%) | 53.54% |
| Sousa, G. J. B., 2020 | Brazil | Retrospective | 2,034 | 1,017/1,053 | NR | CaVD | 66(43%) | 86(57%) | 1,837(97%) | 45(3%) | 7.47% |
| Soares, R.C. M., 2020 | Brazil | Retrospective | 1,152 | 658/494 | NR | CaVD | 270(51%) | 256(49%) | 426(68%) | 200(32%) | 45.66% |
| Nikpouraghdam, M., 2020 | Iran | Retrospective | 2,964 | 1,955/1,099 | NR | CaVD | 33(89%) | 4(11%) | 2,692(92%) | 235(8%) | 1.25% |
| Halvatsiotis, P., 2020 | Greece | Retrospective | 90 | 72/18 | 65.5 (56.0–73.0) | CaVD | 15(80%) | 4(20%) | 45(67%) | 22(33%) | 22.09% |
| Du, R., 2020 | China | Prospective | 179 | 97/82 | NR | CCVD | 17(59%) | 12(41%) | 141(94%) | 9(6%) | 16.20% |
| Yan, Y., 2020 | China | retrospective | 193 | 114/79 | 64.0 (49.0–73.0) | CCVD | 4(10%) | 35(90%) | 81(52%) | 73(48%) | 20.21% |
| Wu, C., 2020 | China | Retrospective | 201 | 127/74 | 51.0 (43.0–60.0) | CaVD | 4(80%) | 16(20%) | 141(78%) | 40(22%) | 9.95% |
| Ruan, Q., 2020 (CeVD) | China | Retrospective | 150 | 102/48 | NR | CeVD | 0(0%) | 13(100%) | 82(60%) | 55(40%) | 8.67% |
| Ruan, Q., 2020 (CaVD) | China | Retrospective | 150 | 102/48 | NR | CaVD | 5(42%) | 7(58%) | 76(55%) | 62(45%) | 8.00% |
| Chen, T., 2020 (CaVD) | China | Retrospective | 274 | 171/103 | 62.0(44.0–70.0) | CaVD | 7(30%) | 16(70%) | 154(61%) | 97(39%) | 8.39% |
| Chen, T., 2020 (CeVD) | China | Retrospective | 274 | 171/103 | 62.0(44.0–70.0) | CeVD | 0(0%) | 4(100%) | 161(60%) | 109(40%) | 1.46% |
| Tu, W. J., 2020 | China | Retrospective | 174 | 79/95 | NR | CCVD | 8(50%) | 8(50%) | 141(89%) | 17(11%) | 9.20% |
| Yuan, M., 2020 | China | Retrospective | 27 | 12/15 | 60.0 (47.0–69.0) | CaVD | 0(0%) | 3(100%) | 17(71%) | 7(29%) | 11.11% |
| Zhou, F., 2020 | China | Retrospective | 191 | 119/72 | 56.0 (46.0–67.0) | CaVD | 2(13%) | 13(87%) | 135(77%) | 41(23%) | 7.85% |
Note. CCVD = cardio-cerebrovascular diseases; CaVD = cardiovascular diseases; CeVD = cerebrovascular diseases; NR = not reported.